TELO Stock Overview
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Telo Genomics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.34 |
| 52 Week Low | CA$0.10 |
| Beta | 1.3 |
| 1 Month Change | 78.26% |
| 3 Month Change | 24.24% |
| 1 Year Change | -24.07% |
| 3 Year Change | -69.85% |
| 5 Year Change | 2.50% |
| Change since IPO | -91.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| TELO | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -5.8% | -0.6% |
| 1Y | -24.1% | -37.3% | 3.9% |
Return vs Industry: TELO exceeded the Canadian Biotechs industry which returned -37.3% over the past year.
Return vs Market: TELO underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| TELO volatility | |
|---|---|
| TELO Average Weekly Movement | 21.4% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: TELO's share price has been volatile over the past 3 months.
Volatility Over Time: TELO's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sabine Mai | www.telodx.com |
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides TeloView-SMM application; TeloView, an analysis software platform for prediction of genomic instability. It has a collaboration agreement with the Mayo Clinic to validate its SMM tests for multiple myeloma.
Telo Genomics Corp. Fundamentals Summary
| TELO fundamental statistics | |
|---|---|
| Market cap | CA$14.62m |
| Earnings (TTM) | -CA$3.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs TELO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELO income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.07m |
| Earnings | -CA$3.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.7% |
How did TELO perform over the long term?
See historical performance and comparison